Compare MXC & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MXC | NEUP |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 23.8M |
| IPO Year | 1995 | N/A |
| Metric | MXC | NEUP |
|---|---|---|
| Price | $8.76 | $5.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 8.8K | ★ 34.7K |
| Earning Date | 02-10-2026 | 05-23-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 30.65 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,705,235.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.20 | ★ N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $6.75 | $3.65 |
| 52 Week High | $16.48 | $21.31 |
| Indicator | MXC | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 53.76 |
| Support Level | $8.57 | $3.91 |
| Resistance Level | $9.65 | $5.45 |
| Average True Range (ATR) | 0.49 | 0.26 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 0.57 | 63.46 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.